Hologic, Inc. $HOLX Shares Sold by Swedbank AB

Key Points

• Swedbank AB has reduced its stake in Hologic, Inc. by 20.7%, selling 263,009 shares and now holding around 1,008,793 shares valued at approximately $62.3 million.
• Despite Swedbank's sell-off, other institutional investors have increased their positions in Hologic, with significant stake increases from firms like Inspire Investing LLC and Empowered Funds LLC.
• Hologic's recent earnings report exceeded expectations, with a net revenue of $1.02 billion and earnings per share of $1.08, prompting upgrades from several analysts regarding their price targets.

Swedbank AB reduced its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 20.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,008,793 shares of the medical equipment provider's stock after selling 263,009 shares during the period. Swedbank AB owned approximately 0.45% of Hologic worth $62,313,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Zions Bancorporation National Association UT bought a new position in shares of Hologic during the first quarter worth about $34,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Hologic during the first quarter worth about $42,000. Raiffeisen Bank International AG bought a new position in shares of Hologic during the fourth quarter worth about $49,000. Allworth Financial LP lifted its position in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the last quarter. Finally, Larson Financial Group LLC lifted its position in shares of Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 722 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HOLX. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Argus raised shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target on the stock in a research report on Monday, August 18th. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and raised their target price for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Finally, UBS Group raised their target price on shares of Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Hologic currently has a consensus rating of "Moderate Buy" and an average price target of $78.62.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $0.34 during trading hours on Thursday, hitting $67.86. The stock had a trading volume of 2,318,021 shares, compared to its average volume of 2,665,150. The stock's fifty day simple moving average is $66.43 and its 200 day simple moving average is $62.69. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The firm has a market capitalization of $15.09 billion, a price-to-earnings ratio of 28.17, a PEG ratio of 2.30 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the business earned $1.06 earnings per share. Hologic's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.